Atara Biotherapeutics, Inc.
http://www.atarabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Atara Biotherapeutics, Inc.
Finance Watch: Merrimack And LianBio Are Latest To Liquidate As Options Run Out
Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Pierre Fabre Hopes To Enter US Cancer Space With Atara’s Ebvallo
Deal Snapshot: The French company already holds rights to the allogeneic T-cell therapy in much of the world, but will pay Atara $30m up front to obtain rights in the US, Canada and elsewhere.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Nina Biotherapeutics, Inc.
- Pinta Biotherapeutics, Inc.
- Santa Maria Biotherapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice